搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
20 小时
Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch
Alnylam Pharmaceuticals has strong growth potential, particularly with Amvuttra for ATTR-CM. Read why ALNY stock justifies a ...
1 天
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...
2 天
Daily on Energy: NRC hears Three Mile Island plans, the latest on oil prices, and Morgan ...
Good afternoon readers, and Happy Friday! We hope you had a great week. In today’s edition of Daily on Energy, Callie and ...
InvestmentNews
2 天
The secret to a successful firm? Invest in company culture
Halbert Hargrove executives shine a spotlight on their strategies, from market resilience and diversification to culture and advisor development.
Newsweek
2 天
Gen Z
The coworkers had to show how they pose for photos and create a love-heart symbol to see if anyone can be as cool as Gen Zers.
dsm.forecastinternational
2 天
Three Insights into FLRAA, the Army’s Next-Gen Rotorcraft
Following the largest domestic defense exhibit focused on the U.S. Army, Future Long Range Assault Attack (FLRAA), the ...
3 天
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next ...
Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT’s ...
3 天
Ponte Vedra pharmaceutical company raises $5.1 million
Cadrenal Therapeutics (Nasdaq: CVKD) announced Thursday it raised $5.1 million by selling an aggregate of 391,243 shares of ...
Medscape
4 天
Gotistobart Trial for NSCLC on Partial Clinical Hold
The FDA placed the hold on the phase 3 PRESERVE-003 trial of the antibody candidate due to varying results between patient ...
5 天
Biogen Still Has Competitive Advantages in Neurology, but Its Moat Looks Narrow
We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...
5 天
How AI-Powered Immunoscience is Transforming Healthcare
Today, there’s an immunoscience renaissance happening, and Sanofi is pushing medical research in this field forward at a much ...
Monroe News
6 天
‘Next Generation’: New Life Church focuses on future of faith
PETERSBURG — Members of New Life Church realize investing in their youth will help secure the future of their faith and build ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈